Paul H. Shield, MD, Inc. v. Northfield Laboratories Inc. (In re Northfield Laboratories Inc.)

467 B.R. 582, 2010 Bankr. LEXIS 2635
CourtUnited States Bankruptcy Court, D. Delaware
DecidedAugust 27, 2010
DocketBankruptcy No. 09-11924 (BLS); Adversary No. 09-53274 (BLS)
StatusPublished
Cited by3 cases

This text of 467 B.R. 582 (Paul H. Shield, MD, Inc. v. Northfield Laboratories Inc. (In re Northfield Laboratories Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Paul H. Shield, MD, Inc. v. Northfield Laboratories Inc. (In re Northfield Laboratories Inc.), 467 B.R. 582, 2010 Bankr. LEXIS 2635 (Del. 2010).

Opinion

MEMORANDUM OPINION 1

BRENDAN LINEHAN SHANNON, Bankruptcy Judge.

Before the Court is (i) the Motion to Dismiss Adversary Proceeding Pursuant [585]*585to Federal Rules of Civil Procedure 12(b)(1), 12(b)(5) and 12(b)(6) [Adv. Docket No. 4] (the “Officer Motion”) filed by defendants Marc Doubleday, George Hides, Jack Kogut, Robert McGinnis, Laurel Omert, and Sophia Twaddell (collectively, the “Officer Defendants” and together with Steven Gould and Northfield Laboratories, Inc., the “Defendants”); and (ii) the Motion of Liquidation Trustee and Steven A. Gould, M.D. to Dismiss Adversary Complaint or in the Alternative for Transfer [Adv. Docket No. 7] (the “Trustee/Gould Motion,” together with the Officer Motion, the “Motions”), seeking dismissal of the complaint (the “Complaint”) filed by the Paul H. Shield, MD, Inc. Money Purchase Plan and the Paul H. Shield, MD, Inc. Profit Sharing Plan (together “Plaintiffs”). The Complaint alleges three claims. The first claim seeks equitable subordination of Defendants’ Former Officer Claims (as defined below). The second and third claims allege that Defendants violated the Securities Exchange Act of 1984.

By the Motions, Defendants request that the Court dismiss the Complaint for lack of subject matter jurisdiction, insufficient service of process, and failure to state a claim upon which relief can be granted pursuant to Federal Rules of Civil Procedure 12(b)(1), (5), and (6), made applicable here by Federal Rule of Bankruptcy Procedure 7012. In the alternative, to the extent that the securities claims are not dismissed, Defendants request that the Court transfer these claims to the United States District Court for the Northern District of Illinois pursuant to 28 U.S.C. § 1412. For the following reasons, the Court will grant the Motions in part.

I. BACKGROUND

On March 17, 2006, Plaintiffs commenced several putative class action lawsuits against Northfield, Dr. Gould, and another former officer in the United States District Court for the Northern District of Illinois (the “Illinois District Court”). The suits were consolidated under the case styled In re Northfield Lab., Inc. Sec. Litig., Case No. 06-C-1493 (the “Securities Litigation”). By the Securities Litigation, Plaintiffs asserted that the defendants therein knowingly issued false and misleading statements and concealed adverse safety and effectiveness information related to Northfield’s sole product, PolyHeme.

More than three years later, on June 1, 2009 (the “Petition Date”) Northfield Laboratories, Inc. (“Northfield” or “Debtor”) filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code. On June 24, 2009, the Office of the United States Trustee for the District of Delaware appointed an official committee of unsecured creditors (the “Committee”) in the Debtor’s case [Docket No. 38]. Plaintiffs’ owner, Paul H. Shield, was appointed as a member of the Committee.

Two days after the Petition Date, on June 3, 2009, the Debtor filed a disclosure statement [Docket No. 19] (the “Original Disclosure Statement”) and a proposed plan of reorganization (as amended, the “Plan”). The Original Disclosure Statement stated that “[t]he principal indebtedness of the Debtor consists of severance obligations under employment contracts with its current and former officers.” (Original Disclosure Statement at 4). The Original Disclosure Statement indicated that the severance obligations (defined in the Plan as the “Former Officer Claims”) would be classified as priority claims or [586]*586general unsecured claims, entitled to Class 1 or Class 2 status, respectively. (Id. at 4). Class 1 claims were to be paid in full and Class 2 claims were to be paid pro rata from any liquidation proceeds. (Id. at 7).

The Plan defined “Securities Claims” to include, inter alia, “any claim for damages or any other relief arising from any ... purchase, sale or other acquisition of ... common stock or other equity security ... including the claims of the plaintiffs in the case styled In re Northfield Laboratories, Inc. Securities Litigation, consolidated under Case Number 06 CV 1493.... ” Plan, App. A, at iv. The Original Disclosure Statement and Plan indicated that Class 3 Securities Claims would receive a distribution “of any available Liquidation Proceeds after the payment and satisfaction of all Class 2 General Unsecured Claims.” (Id.).

Plaintiffs objected [Docket No. 45] to the Original Disclosure Statement arguing that, inter alia, it failed to provide adequate information regarding: (i) the Debt- or’s assets and disposition thereof; (ii) the claims against the Debtor, particularly the Former Officer Claims and the Securities Claims; and (iii) the releases to be granted in the Plan. Plaintiffs also filed a motion to convert the Debtor’s bankruptcy case to one under chapter 7 of the Bankruptcy Code [Docket No. 88], but later withdrew that motion [Docket No. 117].

On August 7, 2009, the Debtor filed an amended disclosure statement (the “Disclosure Statement”) and an amended version of the Plan [Docket Nos. 90 and 91]. The amendments did not alter the distribution scheme whereby Plaintiffs’ Securities Claims were classified below and paid after the Former Officer Claims. Plaintiffs did not object to the amended Plan or the Disclosure Statement.

On August 11, 2009, the Court entered an Order [Docket No. 98] approving the Disclosure Statement over all objections. On September 11, 2009, the Court entered an Order [Docket No. 129] (the “Confirmation Order”) approving the Plan, and on September 25, 2009 (the “Effective Date”), the Plan became effective [See Docket No. 137]. Plaintiffs did not appeal the Order approving the Disclosure Statement or the Confirmation Order.

On the Effective Date, Plaintiffs requested that the Illinois District Court transfer the Securities Litigation to this Court. On November 10, 2009, the Illinois District Court denied Plaintiffs’ request. See In re Northfield Lab., Inc. Sec. Litig., No. 06-cv-01493 (N.D. Ill. Nov. 10, 2009) (order denying transfer motion). In so ruling, the Illinois District Court admonished Plaintiffs against “judge-shopping.” (Id.).

Thereafter, on December 23, 2009, Plaintiffs filed the Complaint commencing this adversary proceeding. Defendants then filed the Motions, Plaintiffs filed a brief in opposition to the Motions [Adv. Docket No. 24], and Defendants filed a joint reply [Adv. Docket No. 25]. The Court heard oral argument on the Motions on July 12, 2010.2 This matter has been fully briefed and is ripe for decision.

II. JURISDICTION

The Court has jurisdiction over this matter pursuant to 28 U.S.C. §§ 1334 and 157. Venue is proper in this Court pursuant to 28 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
467 B.R. 582, 2010 Bankr. LEXIS 2635, Counsel Stack Legal Research, https://law.counselstack.com/opinion/paul-h-shield-md-inc-v-northfield-laboratories-inc-in-re-northfield-deb-2010.